SOPHiA GENETICS (NASDAQ:SOPH) Sees Unusually-High Trading Volume – Here’s What Happened

SOPHiA GENETICS SA (NASDAQ:SOPH) shares saw an uptick in trading volume on Tuesday . 1,310,764 shares were traded during mid-day trading, an increase of 396% from the previous session’s volume of 264,333 shares.The stock last traded at $7.9040 and had previously closed at $7.86.

Wall Street Analyst Weigh In

SOPH has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. HC Wainwright boosted their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. BTIG Research lifted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, SOPHiA GENETICS presently has an average rating of “Hold” and an average price target of $10.00.

SOPHiA GENETICS Price Performance

The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The stock’s 50-day moving average price is $7.08 and its 200-day moving average price is $5.71. The company has a market capitalization of $662.35 million, a price-to-earnings ratio of -6.88 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. Equities research analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Insider Activity at SOPHiA GENETICS

In related news, Chairman Jurgi Camblong sold 8,500 shares of the firm’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $7.66, for a total value of $65,110.00. Following the transaction, the chairman owned 3,435,822 shares in the company, valued at $26,318,396.52. This trade represents a 0.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Well Van sold 6,168 shares of SOPHiA GENETICS stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $7.63, for a total value of $47,061.84. Following the completion of the sale, the insider owned 338,884 shares of the company’s stock, valued at approximately $2,585,684.92. The trade was a 1.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 357,260 shares of company stock valued at $2,317,759 over the last quarter. 4.88% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SOPH. AWM Investment Company Inc. acquired a new stake in shares of SOPHiA GENETICS during the 2nd quarter worth approximately $9,809,000. Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS in the first quarter valued at approximately $2,157,000. Royce & Associates LP acquired a new stake in SOPHiA GENETICS during the 4th quarter worth $2,009,000. Sei Investments Co. acquired a new stake in SOPHiA GENETICS during the 1st quarter worth $1,772,000. Finally, 1492 Capital Management LLC bought a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at $973,000. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company’s platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.

Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data.